Zolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.
This case presents a patient with locally advanced, unresectable, mismatch repair–deficient sigmoid colon cancer who was treated with neoadjuvant chemoimmunotherapy followed by surgical resection leading to a complete pathologic response after preoperative systemic chemoimmunotherapy.
Ibrahim Halil Sahin, MD, and colleagues, explore, the CIRCULATE-US (NRG-GI008; NCT05174169) investigating postoperative ctDNA dynamics in early-stage colon cancer for treatment selection.
Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.
Javier Orozco-Mera, MD, FACS, MSc, discusses signaling pathways and molecular mechanisms involved in the relapse of glioblastoma.
Before closing out their discussion with key takeaways, expert panelists highlight novel non-BCMA targeting bispecifics in the setting of multiple myeloma.
The following was recently published in ASTCT’s Nucleus publication. Follow @ATSTCT for the latest on all-things cellular therapy.
Treatment with durcabtagene autoleucel meets the primary end point of a phase 2 study in relapsed/refractory multiple myeloma.
COVID-19 created unexpected delays in oncologic treatment. This study sought to assess the volume of missed cancer-related services due to the pandemic.
CancerNetwork® spoke with Anthony W. Tolcher, MD, and Alexander I. Spira MD, PhD, about NEXT Oncology partnering with the Phase 1 Trials Program at Virginia Cancer Specialists to give patients another chance at treatment.
The level of scientific evidence in National Comprehensive Cancer Network guidelines for malignant hematological conditions haven’t been recently investigated. Herein, investigators describe the distribution of categories of evidence and consensus among the 10 most common hematologic malignancies with regard to recommendations for staging, initial and salvage therapy, and surveillance.
Closing out their discussion, the panel highlights unmet needs in multiple myeloma that clinicians and patients still face.
The clinical quandary by Langer et al discusses a contralateral late relapse of the original right nonseminomatous germ cell tumors.
The aim of this meta-analysis is to analyze the efficacy of these drugs in the treatment of mCRPC in terms of progression-free survival (PFS) and overall survival (OS), using the results of completed trials.
In this clinical quandary, investigators determine how to best treat patients with opsoclonus-myoclonus–associated neuroblastoma with bone marrow metastases.
ABSTRACT Advances in immuno-oncology over the last several years have led to FDA approvals of novel agents. As our understanding of immune response and its checkpoints has evolved, further advances have been made in treatment for several cancer types. To predict a response to immunotherapy, the initial biomarkers used were expression of the PD-1 receptor and PD-L1, as assessed by immunohistochemistry. More recently, predictive biomarkers have included microsatellite instability, DNA mismatch repair, and tumor mutational burden. Although these markers may be clinically relevant in predicting an immunotherapy response, cancer immunotherapy fails some patients. Improved understanding of the human immune system is necessary, as is a careful evaluation of the methods used to predict and assess response to Immuno-oncology treatments. With the application of therapeutic immune-modulating agents, more comprehensive assays, and associated bioinformatics tools to accurately assess the tumor microenvironment, we may better predict responses to immuno-oncology agents and the ever-increasing complexity of their clinical use.
Rohit Gupta, MD, et al review a case study of a 70-year-old man who presented with a head mass, and the final diagnosis was hepatocellular carcinoma.
Experts in the field review integration of approved PARP inhibitors into advanced prostate cancer clinical practice.